FindTrial
Sign In

Evaluating quality of life in patients with non-small cell lung cancer treated with Nivolumab

Evaluating quality of life in patients with non-small cell lung cancer treated with Nivolumab - Evaluating quality of life in patients with non-small cell lung cancer treated with Nivolumab

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000022427
Enrollment
50
Registered
2016-10-30
Start date
2016-04-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Sponsors

Sasebo City General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Stage IIIB or IV non-small cell lung cancer, Histologically or cytologically confirmed Non-small cell lung cancer patients with treatment history ECOG performance status must be 0-2 Acquisition of written informed consent

Exclusion criteria

Exclusion criteria: Patients without notification of their cancer disease Patients with potential disease affecting QOL survey and handgrip test. Those judged to be not suitable by the attending physician

Design outcomes

Primary

MeasureTime frame
QOL evaluation (FACT-L)—

Countries

Japan

Contacts

Public ContactOgawara Daiki

Sasebo City General Hospital Respiratory medicine

dogawara@hospital.sasebo.nagasaki.jp0956-24-1515

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026